Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • How AI is Transforming Health Literacy and Engagement

    AI tools help patients better understand coverage and costs, choose the right providers, and stay on track with care while reducing administrative burden for providers and payers.

    Read more

  • Two William Blair Clients Named Middle-Market Deals of the Year by Mergers & Acquisitions

    Congratulations to William Blair clients Commodity & Ingredient Hedging LLC, a portfolio company of Falfurrias Capital Partners, and Stout, a portfolio company of Audax Private Equity, for being recognized on Mergers & Acquisitions’ list of 2026 Mid-Market Deals of the Year.

    Read more

  • College Was Awesome. Now What?

    College graduation marks the start of a career with new responsibilities and decisions. It can be an exciting time but filled with uncertainty.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures